New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2013
07:12 EDTPVCTProvectus Pharmaceuticals held Type C meeting with FDA on December 16th
Provectus Pharmaceuticals held a Type C meeting with the FDA’s Division of Oncology Products 2 on December 16. The purpose of the meeting was to determine which of the available paths that Provectus’ novel oncology drug PV-10 will take in pursuit of FDA approval and commercialization. The agency should issue official minutes to the company by January 15, 2014. The minutes will allow the company to better estimate a time-line to commercialization of PV-10.
News For PVCT From The Last 14 Days
Check below for free stories on PVCT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PVCT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use